[
  {
    "ts": "2026-02-11T11:45:00+00:00",
    "headline": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
    "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
    "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f1e04c13-ee6a-337d-bb05-8f200b17e962",
      "content": {
        "id": "f1e04c13-ee6a-337d-bb05-8f200b17e962",
        "contentType": "STORY",
        "title": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
        "description": "",
        "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
        "pubDate": "2026-02-11T11:45:00Z",
        "displayTime": "2026-02-11T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad",
          "originalWidth": 1000,
          "originalHeight": 404,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PQWewlSpOjq3LBzkeZ9umg--~B/aD00MDQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad.cf.webp",
              "width": 1000,
              "height": 404,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W0iu6UMRdyYDW2qH3YUL1w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "A"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T11:45:00+00:00",
    "headline": "KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment",
    "summary": "RAHWAY, N.J., February 11, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] ≥1), as determined by an FDA-authorized test, platinum-resistant epithelial ovarian, fallopian tube or primary peri",
    "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-keytruda-qlex-pembrolizumab-114500543.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "c8ec4c16-ad8d-379c-a2ff-3e4a670c6cbd",
      "content": {
        "id": "c8ec4c16-ad8d-379c-a2ff-3e4a670c6cbd",
        "contentType": "STORY",
        "title": "KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment",
        "description": "",
        "summary": "RAHWAY, N.J., February 11, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] ≥1), as determined by an FDA-authorized test, platinum-resistant epithelial ovarian, fallopian tube or primary peri",
        "pubDate": "2026-02-11T11:45:00Z",
        "displayTime": "2026-02-11T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/f72da739c2e0b49c6898cb43374a6ce8",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1JjbPKxa0fNwykIPHSn07Q--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f72da739c2e0b49c6898cb43374a6ce8.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DWh5.dfw..6c4V5JHnFoJw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f72da739c2e0b49c6898cb43374a6ce8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-keytruda-qlex-pembrolizumab-114500543.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-keytruda-qlex-pembrolizumab-114500543.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T13:09:00+00:00",
    "headline": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
    "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
    "url": "https://finance.yahoo.com/news/pfizers-acquired-drugs-offset-looming-130900387.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ea2b5616-f63a-34ac-95ef-b1e424566e82",
      "content": {
        "id": "ea2b5616-f63a-34ac-95ef-b1e424566e82",
        "contentType": "STORY",
        "title": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
        "description": "",
        "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
        "pubDate": "2026-02-11T13:09:00Z",
        "displayTime": "2026-02-11T13:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ffSS19YaoL36xXdlr0Ip4A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mJhhM1.2_VWzkATXxZYL_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-acquired-drugs-offset-looming-130900387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-acquired-drugs-offset-looming-130900387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]